Lab supply companies have been selling antibodies using manipulated images

Lab supply companies have marketed over 17,500 commercial antibodies using manipulated images in product demonstrations, with nearly 7% of examined images showing signs of problematic alterations ranging from noise removal to data fabrication. This discovery poses significant operational and compliance risks for R&D organizations, as researchers may waste substantial time and resources troubleshooting ineffective products, while also raising questions about supplier quality assurance and data integrity practices across the life sciences industry. IT leaders must recognize this as a broader indicator of potential data governance gaps in vendor systems and the need for enhanced due diligence protocols in scientific supply chain management.